REGN: Record growth brands and a broad pipeline drove strong Q3 results and higher planned R&D

What happened

Regeneron reported third-quarter revenue growth of 36% and non-GAAP earnings per share growth of 70%, with record sales for DUPIXENT, EYLEA HD, and LIBTAYO. The company said planned research and development spending will accelerate, with 2027 R&D expense expected to rise at a mid-teens rate.

Confirmed

Global impact / market context

Faster revenue and profit growth fund a larger research budget. Because research spending is a cost recorded before future products earn money, investors must weigh near-term profit pressure against the chance of new drugs refilling the pipeline as older products mature.

Analyst inference

Regeneron is a large drugmaker whose shares trade on expectations for its existing blockbuster medicines and future pipeline. A rising research budget signals confidence but lowers near-term earnings, so shareholder returns depend on whether new treatments reach the market.

Analyst inference

What to watch

1. Watch whether DUPIXENT, EYLEA HD, and LIBTAYO keep setting record sales, since these products currently drive the company's reported revenue growth. Confirmed
2. Track how much of the planned research and development increase goes toward late-stage trials, which cost more but sit closer to earning regulatory approval and sales. Proposed
3. Observe whether the mid-teens 2027 research spending rise slows profit growth, because higher costs can offset revenue gains before new medicines launch. Analyst inference

Evidence

• Original source link unavailable